Meghna Sen

During the quarter, Royal Enfield recorded sales of 2.25 lakh motorcycles as compared to 2.29 lakh motorcycles sold during the same period in FY24.

After a flat opening on Wednesday, the Nifty 50 index gradually drifted lower, retesting its critical support at the 200-day exponential moving average (DEMA) for the first time in nearly five months.

Nuva Bupa is expected to have a post-listing market capitalisation of ₹13,520 crore at the upper end of the price band.

Royal Enfield's domestic sales edged down 1% year-on-year in the first half of the financial year 2025. However, a strong recovery is expected in the second half, with an anticipated 12% year-on-year increase driven by strong festive demand, a sharper focus on key models (Classic, Bullet), and a push for new products and marketing.

Out of the 17 analysts that track BHEL, nine of them have a 'Sell' rating on the counter with price targets ranging to as low as ₹61, to as high as ₹371.

Niva Bupa Health Insurance IPO: Niva Bupa has demonstrated strong growth and a positive turnaround in recent years. However, the recent negative earnings in the first quarter of the current financial year has raised concerns about its short-term performance.

The company's capital expenditure plans of ₹525 crore for backward integration and strengthening the supply chain (PET bottles) is expected to aid in margin expansion over the long term.

Shares of Akums Drugs are currently in a lower circuit of 5% at ₹582.10. The stock is now 14% away from its IPO price of ₹679.

The Board of IPCA Laboratories has declared an interim dividend of ₹21 per equity share for the financial year 2024-25. Record date for the same has been fixed as November 25, 2024.

Nava Ltd. will split one share with a face value of ₹2 into two shares of face value of ₹1. Record date for the said split will be fixed and intimated in due course.